{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:22:30Z","timestamp":1776306150910,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T00:00:00Z","timestamp":1447027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11102-015-0691-0","type":"journal-article","created":{"date-parts":[[2015,11,9]],"date-time":"2015-11-09T02:56:29Z","timestamp":1447037789000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY"],"prefix":"10.1007","volume":"19","author":[{"name":"Spanish ACROSTUDY Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bernabeu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Venegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Aller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Alvarez-Escol\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Garc\u00eda-Arn\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marazuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,9]]},"reference":[{"issue":"16","key":"691_CR1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171\u20131177","journal-title":"N Engl J Med"},{"issue":"9295","key":"691_CR2","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ Lely van der","year":"2001","unstructured":"van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295):1754\u20131759","journal-title":"Lancet"},{"issue":"5","key":"691_CR3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","volume":"23","author":"JJ Kopchick","year":"2002","unstructured":"Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23(5):623\u2013646","journal-title":"Endocr Rev"},{"issue":"16","key":"691_CR4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJM200004203421611","volume":"342","author":"RD Utiger","year":"2000","unstructured":"Utiger RD (2000) Treatment of acromegaly. N Engl J Med 342(16):1210\u20131211","journal-title":"N Engl J Med"},{"issue":"1","key":"691_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/eje.1.02312","volume":"156","author":"I Schreiber","year":"2007","unstructured":"Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156(1):75\u201382. doi: 10.1530\/eje.1.02312","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"691_CR6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-09-0350","volume":"161","author":"M Buchfelder","year":"2009","unstructured":"Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Strasburger CJ (2009) The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3\u2013S10. doi: 10.1530\/EJE-09-0350","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 5","key":"691_CR7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000110481","volume":"68","author":"CJ Strasburger","year":"2007","unstructured":"Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK, Saller B (2007) Experience from the German pegvisomant observational study. Horm Res 68(Suppl 5):70\u201373. doi: 10.1159\/000110481","journal-title":"Horm Res"},{"issue":"2","key":"691_CR8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/eje.1.02079","volume":"154","author":"H Biering","year":"2006","unstructured":"Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154(2):213\u2013220. doi: 10.1530\/eje.1.02079","journal-title":"Eur J Endocrinol"},{"key":"691_CR9","author":"C Sievers","year":"2009","unstructured":"Sievers C, Brubach K, Saller B, Schneider HJ, Buchfelder M, Droste M, Mann K, Strasburger CJ, Stalla GK (2009) Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol (Oxf). doi: 10.1111\/j.1365-2265.2009.03773.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"691_CR10","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","volume":"161","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19\u2013S24. doi: 10.1530\/EJE-09-0322","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 5","key":"691_CR11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000110480","volume":"68","author":"PJ Trainer","year":"2007","unstructured":"Trainer PJ (2007) ACROSTUDY: an overview. Horm Res 68(Suppl 5):68\u201369. doi: 10.1159\/000110480","journal-title":"Horm Res"},{"issue":"Suppl 1","key":"691_CR12","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1530\/EJE-09-0333","volume":"161","author":"T Brue","year":"2009","unstructured":"Brue T, Castinetti F, Lundgren F, Koltowska-Haggstrom M, Petrossians P (2009) Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol 161(Suppl 1):S11\u2013S17. doi: 10.1530\/EJE-09-0333","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"691_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000178035","volume":"71","author":"T Brue","year":"2009","unstructured":"Brue T (2009) ACROSTUDY: status update on 469 patients. Horm Res 71(Suppl 1):34\u201338. doi: 10.1159\/000178035","journal-title":"Horm Res"},{"issue":"5","key":"691_CR14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","volume":"97","author":"AJ Lely van der","year":"2012","unstructured":"van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Haggstrom M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589\u20131597. doi: 10.1210\/jc.2011-2508","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"691_CR15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4158\/EP14330.OR","volume":"21","author":"PU Freda","year":"2015","unstructured":"Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (2015) Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 21(3):264\u2013274","journal-title":"Endocr Pract"},{"key":"691_CR16","author":"S Grottoli","year":"2014","unstructured":"Grottoli S, Maffei P, Bogazzi F, Cannavo S, Colao A, Ghigo E, Gomez R, Graziano E, Monterubbianesi M, Jonsson P, De Marinis L (2014) ACROSTUDY: the Italian experience. Endocrine. doi: 10.1007\/s12020-014-0393-9","journal-title":"Endocrine"},{"issue":"3","key":"691_CR17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03344942","volume":"16","author":"J Etxabe","year":"1993","unstructured":"Etxabe J, Gaztambide S, Latorre P, Vazquez JA (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16(3):181\u2013187","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"691_CR18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/eje.0.1510439","volume":"151","author":"A Mestron","year":"2004","unstructured":"Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439\u2013446","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"691_CR19","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1210\/jc.2009-2547","volume":"95","author":"I Bernabeu","year":"2010","unstructured":"Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-Escola C, Luque-Ramirez M, Fernandez-Rodriguez E, Paniagua AE, Quinteiro C, Casanueva FF (2010) Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert\u2019s syndrome. J Clin Endocrinol Metab 95(5):2147\u20132154. doi: 10.1210\/jc.2009-2547","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"691_CR20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-13-0657","volume":"170","author":"M Filopanti","year":"2014","unstructured":"Filopanti M, Barbieri AM, Mantovani G, Corbetta S, Gasco V, Ragonese M, Martini C, Bogazzi F, Colao A, Ferone D, Peri A, Pigliaru F, Angeletti G, Arosio M, Beck-Peccoz P, Lania AG, Spada A (2014) Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. Eur J Endocrinol 170(2):247\u2013254. doi: 10.1530\/EJE-13-0657","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"691_CR21","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","volume":"99","author":"SJ Neggers","year":"2014","unstructured":"Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ, Jorgensen JO, van der Lely AJ (2014) Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab 99(10):3644\u20133652. doi: 10.1210\/jc.2014-2032","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"691_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","volume":"153","author":"GM Besser","year":"2005","unstructured":"Besser GM, Burman P, Daly AF (2005) Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 153(2):187\u2013193. doi: 10.1530\/eje.1.01968","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"691_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-08-0910","volume":"161","author":"M Buchfelder","year":"2009","unstructured":"Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Bidlingmaier M, Strasburger CJ (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161(1):27\u201335. doi: 10.1530\/EJE-08-0910","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"691_CR24","doi-asserted-by":"crossref","first-page":"E251","DOI":"10.1210\/jc.2010-1742","volume":"96","author":"M Marazuela","year":"2011","unstructured":"Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escola C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castano JP, Bernabeu I (2011) Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab 96(2):E251\u2013E259. doi: 10.1210\/jc.2010-1742","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"691_CR25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/EJE-14-0844","volume":"172","author":"C Schofl","year":"2015","unstructured":"Schofl C, Grussendorf M, Honegger J, Tonjes A, Thyroke-Gronostay D, Mayr B, Schopohl J, participants of the German Acromegaly R (2015) Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur J Endocrinol 172(4):351\u2013356. doi: 10.1530\/EJE-14-0844","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"691_CR26","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2008-0391","volume":"93","author":"M Mercado","year":"2008","unstructured":"Mercado M, Gonzalez B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL, Sosa E (2008) Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 93(9):3411\u20133415. doi: 10.1210\/jc.2008-0391","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"691_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1210\/jc.2009-1630","volume":"95","author":"I Bernabeu","year":"2010","unstructured":"Bernabeu I, Alvarez-Escola C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramirez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M (2010) The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95(1):222\u2013229. doi: 10.1210\/jc.2009-1630","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"691_CR28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2008-1337","volume":"94","author":"A Bianchi","year":"2009","unstructured":"Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94(6):2015\u20132022. doi: 10.1210\/jc.2008-1337","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"691_CR29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ghir.2010.09.001","volume":"20","author":"F Akin","year":"2010","unstructured":"Akin F, Turgut S, Cirak B, Kursunluoglu R (2010) IGF(CA)19 and IGFBP-3-202A\/C gene polymorphism in patients with acromegaly. Growth Horm IGF Res 20(6):399\u2013403. doi: 10.1016\/j.ghir.2010.09.001","journal-title":"Growth Horm IGF Res"},{"key":"691_CR30","author":"AM Ramos-Levi","year":"2014","unstructured":"Ramos-Levi AM, Marazuela M, Paniagua A, Quinteiro C, Riveiro J, Alvarez-Escola C, Lucas T, Blanco C, Paz DM, Martinez de Icaya P, Pavon I, Bernabeu I (2014) Analysis of Igf(Ca)19 and Igfpb3 202a\/C gene polymorphisms in patients with acromegaly: association with clinical presentation and response to treatments. Eur J Endocrinol. doi: 10.1530\/EJE-14-0613","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"691_CR31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1530\/EJE-08-0705","volume":"160","author":"M Marazuela","year":"2009","unstructured":"Marazuela M, Lucas T, Alvarez-Escola C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramirez M, Halperin I, Casanueva FF, Bernabeu I (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160(4):535\u2013542. doi: 10.1530\/EJE-08-0705","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"691_CR32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","volume":"92","author":"C Parkinson","year":"2007","unstructured":"Parkinson C, Burman P, Messig M, Trainer PJ (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92(1):190\u2013195. doi: 10.1210\/jc.2006-1412","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"691_CR33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/er.2003-0035","volume":"25","author":"KC Leung","year":"2004","unstructured":"Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25(5):693\u2013721. doi: 10.1210\/er.2003-0035","journal-title":"Endocr Rev"},{"issue":"1","key":"691_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-13-0438","volume":"171","author":"M Droste","year":"2014","unstructured":"Droste M, Domberg J, Buchfelder M, Mann K, Schwanke A, Stalla G, Strasburger CJ (2014) Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol 171(1):59\u201368. doi: 10.1530\/EJE-13-0438","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"691_CR35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-10-0867","volume":"164","author":"AJ Lely van der","year":"2011","unstructured":"van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P (2011) Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164(3):325\u2013333. doi: 10.1530\/EJE-10-0867","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"691_CR36","first-page":"4712","volume":"85","author":"KC Leung","year":"2000","unstructured":"Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK (2000) Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 85(12):4712\u20134720","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"691_CR37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0006-291X(78)90177-8","volume":"84","author":"RC Baxter","year":"1978","unstructured":"Baxter RC, Turtle JR (1978) Regulation of hepatic growth hormone receptors by insulin. Biochem Biophys Res Commun 84(2):350\u2013357","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"691_CR38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF00569572","volume":"32","author":"MI Wurzburger","year":"1995","unstructured":"Wurzburger MI, Prelevic GM, Sonksen PH, Wheeler M, Balint-Peric L (1995) Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol 32(2):131\u2013134","journal-title":"Acta Diabetol"},{"issue":"1","key":"691_CR39","first-page":"267","volume":"77","author":"MI Wurzburger","year":"1993","unstructured":"Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA, Wheeler M (1993) The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab 77(1):267\u2013272. doi: 10.1210\/jcem.77.1.8325951","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"691_CR40","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1365-2265.1996.672494.x","volume":"44","author":"J Kratzsch","year":"1996","unstructured":"Kratzsch J, Keliner K, Zilkens T, Schmidt-Gayk H, Selisko T, Scholz GH (1996) Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus. Clin Endocrinol (Oxf) 44(6):673\u2013678","journal-title":"Clin Endocrinol (Oxf)"},{"key":"691_CR41","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1530\/eje.0.148S027","volume":"148","author":"PM Stewart","year":"2003","unstructured":"Stewart PM (2003) Pegvisomant: an advance in clinical efficacy in acromegaly. Eur J Endocrinol 148:S27\u2013S32","journal-title":"Eur J Endocrinol"}],"updated-by":[{"DOI":"10.1007\/s11102-016-0719-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T00:00:00Z","timestamp":1462320000000}}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-015-0691-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-015-0691-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-015-0691-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T02:08:24Z","timestamp":1559354904000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-015-0691-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,9]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s11102-015-0691-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11102-016-0719-0","asserted-by":"object"}]},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,9]]}}}